Damaged Biotech, Reverse Merger Threat

Eliem Therapeutics (ELYM) ($67MM market cap) is a damaged biotech that beforehand was centered on growing therapies for psychological well being and central nervous system issues. Again in February of this 12 months, Eliem paused improvement on ETX-155 resulting from “difficult capital surroundings” regardless of having FDA help for a Section 2 trial to deal with main depressive dysfunction.  Factors to some attainable worth and expense self-discipline.  The corporate did a discount in workforce of 55% and refocused on the pre-clinical ETX-123. As we have seen with others, they ended up totally pausing all analysis and improvement in July, introduced plans to discover strategic alternate options and accomplished an extra workforce discount (which is captured within the severance prices under).

This one is slightly straight ahead, there is no debt, minimal lease obligations, ~$100MM of money and a 49% shareholder in RA Capital.

RA Capital is an institutional participant in life sciences, they make investments throughout the pre-revenue/income spectrum, Andrew Levin from RA Capital is the chairman of the board for ELYM. He seems to be extra of a scientist than an investor, however I am certain straddles each.  All that to remain this case most likely leans in the direction of a reverse merger — it has been 4+ months because the strategic alternate options announcement, a scientist as chairman and controlling shareholder (might need one thing they personal privately and wish to carry public), however given the possession alignment, hopefully a properly thought out transaction.  The IP may also be value one thing right here to somebody desirous to pursue a Section 2 trial for ETX-155.